{
  "ptid_time": "041_S_4051_2011-06-22",
  "img_path": "/data/qiuhui/data/adni/images/041_S_4051/2011-06-22/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 43,966 mm³, 14.1% above the reference mean. With a Z-score of 0.34 (63.3th percentile), this represents normal volume ; hippocampal volume measures 8,494 mm³, 12.4% above the reference mean. With a Z-score of 1.21 (88.6th percentile), this represents mild enlargement; whole brain volume measures 1,278,840 mm³, 18.5% above the reference mean. With a Z-score of 2.40 (99.2th percentile), this represents significant enlargement; entorhinal cortex volume measures 4,830 mm³, 17.8% above the reference mean. With a Z-score of 1.21 (88.6th percentile), this represents mild enlargement; fusiform gyrus volume measures 24,315 mm³, 29.1% above the reference mean. With a Z-score of 2.48 (99.3th percentile), this represents significant enlargement; middle temporal gyrus volume measures 26,724 mm³, 25.2% above the reference mean. With a Z-score of 2.27 (98.8th percentile), this represents significant enlargement. ",
  "text_data": "Age is 70.6 years. Gender is Male. Education: 16 years. Handedness: Right. Race: White. Medical history: Head, Eyes, Ears, Nose and Throat; Cardiovascular; Musculoskeletal; Endocrine-Metabolic; Major Surgical Procedures. MMSE: 29.0. MoCA: 21.0. Logical Memory: 9.0. Laboratory findings: Neutrophils: 78.00 (significant elevated); WBC: 10.91 (profound elevated); Neutrophils: 8.51 (profound elevated). APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.06 SUVR (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The brain volume measurements show significant enlargement in multiple regions (whole brain, fusiform gyrus, middle temporal gyrus) and mild enlargement in others (hippocampus, entorhinal cortex), which is atypical for Alzheimer's disease (AD) where atrophy is expected. The MMSE score (29/30) is normal, but the MoCA (21/30) suggests mild cognitive impairment (MCI). The absence of APOE4 and normal AV45 (amyloid PET) further reduces the likelihood of AD.  \n\n**Diagnosis:** **MCI** (likely non-amyloid/non-AD etiology given volumetric and biomarker findings).  \n**Confidence:** **Medium** (volumetric enlargement is unusual and may reflect an atypical neurodegenerative process or non-degenerative cause; MoCA impairment is notable but not severe).",
  "timestamp": "2025-07-26T07:11:12.498342"
}